High Dose: 15mg BPC-157 + 15mg TB-500 (2mL vial 7.5mg/mL each)
The association between between COVID-19 and cardiovascular comorbidities may relate to the pleiotropic role of ACE2 1, 9
Disorders of fat metabolism: Rare genetic disorders of lipid metabolism may be a contraindication (e.g., hyperlipoproteinemia)
Small pilot studies have examined GLP-1 receptor agonists in individuals with alcohol use disorder
So far, there are no published randomized, controlled trials investigating pharmacological treatment options for fluid intake in primary polydipsia
Retatrutide metabolic benefits Retatrutide produces all of the metabolic benefits seen with Mounjaro plus additional improvements that appear unique to triple agonism: Blood sugar control: HbA1c reductions of 1.3% to 2.0% at doses of 4-12 mg in type 2 diabetes Blood pressure: Systolic blood pressure reduction of up to 14.0 mmHg at the highest dose (roughly double what Mounjaro achieves) Lipids: Non-HDL cholesterol and triglyceride reductions Prediabetes reversal: 72% of participants with prediabetes at baseline reverted to normoglycemia Inflammatory markers: Significant reductions in high-sensitivity C-reactive protein But the standout metabolic benefit, the one that has researchers most excited, is the effect on liver health